Today’s Research Reports on Trending Tickers: Valeant Pharmaceuticals and Nektar Therapeutics
U.S. equities plunged on Friday, but finished the week on a positive note, as bank earnings failed to lift market optimism amidst geopolitical anxiety. The Dow Jones Industrial Average dropped 0.50 percent to close at 24,360.14, ending the week 1.8 percent higher, while the S&P 500 Index fell 0.29 percent to close at 2,656.30, gained 2 percent for the week. The Nasdaq Composite Index declined 0.47 percent to close at 7,106.65, jumped 2.8 percent for the week.
“The bank earnings looked decent, but they weren’t spectacular, and they certainly weren’t great enough to push the stocks over important technical resistance,” said Wayne Kaufman, chief market analyst at Phoenix Financial Services.
RDI Initiates Coverage on:
Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals’ stock moved 3.13% higher Friday, to close the day at $17.15. The stock recorded a trading volume of 10,802,535 shares, which was below its three months average volume of 11,083,241 shares. In the last year, Valeant Pharmaceuticals’ shares have traded in a range of 8.31 – 24.43. The share price has gained 106.38% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $16.02 is below its 200-day moving average of $17.05. Shares of the company are trading at a Price to Earnings ratio of 2.51. Shares of Valeant Pharmaceuticals have gained roughly 2.54 percent in the past month and are down 17.47 percent year-to-date.
Access RDI’s Valeant Pharmaceuticals International, Inc. Research Report at:
On Friday, shares of Nektar Therapeutics recorded a trading volume of 1,082,724 shares, which was below the three months average volume of 3,093,966 shares. The stock ended the day 3.12% lower at 100.50. The share price has gained 479.92% from its 52 week low with a 52 week trading range of 17.33 – 111.36. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $99.58 is greater than its 200-day moving average of $61.08. Shares of Nektar Therapeutics have fallen roughly 1.48 percent in the past month and are up 68.29 percent year-to-date.
Access RDI’s Nektar Therapeutics Research Report at:
Our Actionable Research on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) and Nektar Therapeutics (NASDAQ:NKTR) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.